EUVIMEDEUVIMED entdecken
MetaanalyseSystematische Übersicht

The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials

Giada Pinterpe, Fortuna Migliaccio, Chiara Ciccarese, Romina Rose Pedone, Rachele Belletto, Pierluigi Russo, Angelo Totaro, Luca Tagliaferri, Chiara Sighinolfi, Luigi Formisano, Rossana Berardi, Bernardo Rocco und 2 weitere

Targeted Oncology · 2025

DOI: 10.1007/s11523-025-01141-9 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Targeted Oncology, 2025. Verfasst von Giada Pinterpe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Clinica Oncologica e Centro Regionale di Genetica Oncologica, AOU delle Marche, Ancona, Italy. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Poly(ADP-ribose) Polymerase Inhibitors, Recombinational DNA Repair. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA1/2 mutations show significant responses to poly-ADP ribose polymerase inhibitors (PARPi), while the efficacy of these agents in patients with homologous recombination repair (HRR) gene alterations other than BRCA remains unclear. OBJECTIVE: This meta-analysis aimed at assessing the efficacy of PARPi in mCRPC harboring alterations in four rare HRR genes (i.e. CDK12, PALB2, ATM, and CHEK2). PATIENTS AND METHODS: Five randomised phase III trials (PROfound, PROpel, MAGNITUDE, TALAPRO-2, TRITON3) were selected through searching the Medline/PubMed, Cochrane Library, and ASCO Meeting abstracts. Data extraction followed the PRISMA statement. The primary endpoints, radiographic progression-free survival (rPFS) and overall survival (OS) with the relative 95% CI, were calculated using fixed- or random-effects methods, depending on the studies' heterogeneity. RevMan software for meta-analysis (v.5.2.3) was used. RESULTS: PARPi significantly improved rPFS in mCRPC patients with CDK12 alterations (hazard ratio (HR) = 0.65; p = 0.02) without OS benefit. In patients with ATM, CHEK2, or PALB2 alterations, no significant benefit was observed in rPFS or OS. Due to the low incidence of these rare mutations, we grouped them into gene panels, revealing a significant rPFS advantage when CDK12+PALB2 (HR = 0.63; p = 0.009) were combined, and a similar benefit when including CHEK2 in the gene panel (HR = 0.69; p = 0.01). CONCLUSION: CDK12 alterations could be considered as a predictive biomarker of rPFS benefit with PARPi. A gene panel grouping CDK12 and PALB2 with or without CHEK2 mutations could also enable prediction of rPFS benefit with PARPi.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantPoly(ADP-ribose) Polymerase InhibitorsRecombinational DNA RepairHumansMaleRandomized Controlled Trials as TopicNeoplasm Metastasis

Substanzen

Poly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Clinica Oncologica e Centro Regionale di Genetica Oncologica, AOU delle Marche, Ancona, Italy.
  • Department of Clinical Medicine and Surgery, University of Naples "Federico II", Napoli, Italy.
  • Medical Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Largo Agostino Gemelli 8, 00158, Rome, Italy. chiara.ciccarese@policlinicogemelli.it.
  • Università Cattolica del Sacro Cuore, Facoltà di Medicina e Chirurgia, Rome, Italy.
  • Urology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Department of Radiation Oncology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy.

Zitieren

APA

Pinterpe, G., Migliaccio, F., Ciccarese, C., Pedone, R. R., Belletto, R., Russo, P., Totaro, A., Tagliaferri, L., Sighinolfi, C., Formisano, L., Berardi, R., Rocco, B., Tortora, G., & Iacovelli, R. (2025). The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials. Targeted Oncology. https://doi.org/10.1007/s11523-025-01141-9

Vancouver

Pinterpe G, Migliaccio F, Ciccarese C, Pedone RR, Belletto R, Russo P, et al. The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials. Targeted Oncology. 2025. doi:10.1007/s11523-025-01141-9

BibTeX
@article{Pinterpe2025,
  author = {Pinterpe, Giada and Migliaccio, Fortuna and Ciccarese, Chiara and Pedone, Romina Rose and Belletto, Rachele and Russo, Pierluigi and Totaro, Angelo and Tagliaferri, Luca and Sighinolfi, Chiara and Formisano, Luigi and Berardi, Rossana and Rocco, Bernardo and Tortora, Giampaolo and Iacovelli, Roberto},
  title = {The Impact of Uncommon HRR Alterations as Predictors of Efficacy of PARP Inhibitors in Metastatic Castration-Resistant Prostate Cancer: A Meta-Analysis of Randomized Controlled Trials},
  journal = {Targeted Oncology},
  year = {2025},
  doi = {10.1007/s11523-025-01141-9}
}
Kostenlos starten →